Amino Acids

, Volume 14, Issue 1–3, pp 175–179 | Cite as

Destruction of catecholamine-containing neurons by 6-hydroxydopa, an endogenous amine oxidase cofactor

  • R. M. Kostrzewa
  • R. Brus
Review Article


The amino acid, 6-hydroxydopa (6-OHDOPA), found at the active site of amine oxidases, exists as a keto-enol. Exogenously administered 6-OHDOPA is an excitotoxin likeβ-N-oxalylamino-L-alanine (BOAA) andβ-N-methylamino-L-alanine (BMAA), acting at the non-N-methyl-D-aspartate (non-NMDA)α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor. BMAA and BOAA are causal factors of neurolathyrism in humans. Much exogenously administered 6-OHDOPA is biotransformed by aminoacid decarboxylase (AADC) to the highly potent and catecholamine (CA) selective neurotoxin, 6-hydroxydopamine (6-OHDA). 6-OHDOPA destroys locus coeruleus noradrenergic perikarya and produces associated denervation of brain by norepinephrine-(NE) containing fibers. Opiopeptides and opioids enhance neurotoxic effects of 6-OHDOPA on noradrenergic nerves, by a naloxone-reversible process. An understanding of mechanisms underlying neurotoxic effects of 6-OHDOPA can be helpful in defining actions of known and newfound amino acids and for investigating their potential neurotoxic properties.


6-Hydroxydopa 6-Hydroxydopamine Noradrenergic neurons Neurotoxicity Excitatory amino acids 



aminoacid decarboxylase


α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid










excitatory amino acid












standard error of the mean


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cha JH, Dure LS, Sakurai SY, Penney JB, Young AB (1991) 2,4,5-Trihydroxyphenylalanine (6-hydroxy-dopa) displaces [3H]AMPA binding in rat striatum. Neurosci Lett 132: 55–58Google Scholar
  2. Clark MB, King JC, Kostrzewa RM (1979) Loss of nerve cell bodies in caudal locus coeruleus following treatment of neonates with 6-hydroxydopa. Neurosci Lett 13: 331–336Google Scholar
  3. Harston CT, Clark MB, Hardin JC, Kostrzewa RM (1981) Opiate-enhanced toxicity and noradrenergic sprouting in rats treated with 6-hydroxydopa. Eur J Pharm 71: 365–373Google Scholar
  4. Jacobowitz D, Kostrzewa R (1971) Selective action of 6-hydroxydopa on noradrenergic terminals: mapping of preterminal axons of the brain. Life Sci 10: 1329–1341Google Scholar
  5. Janes SM, Mu D, Wemmer D, Smith AJ, Kaur S, Maltby D, Burlingame AL (1990) A new redox cofactor in eukaryotic enzymes: 6-hydroxydopa at the active site of bovine serum amine oxidase. Science 248: 981–987Google Scholar
  6. Kostrzewa RM (1998) 6-Hydroxydopa, a catecholamine neurotoxin and endogenous excitotoxin at non-NMDA receptors. In: Kostrzewa RM (ed) Highly selective neurotoxins: basic and clinical applications. Humana Press, Totowa, NJ (in press)Google Scholar
  7. Kostrzewa RM, Garey RE (1977) Sprouting of noradrenergic terminals in rat cerebellum following neonatal treatment with 6-hydroxydopa. Brain Res 124: 385–391Google Scholar
  8. Kostrzewa RM, Harper JW (1974) Effects of 6-hydroxydopa on catecholamine-containing neurons in brains of newborn rats. Brain Res 69: 174–181Google Scholar
  9. Kunig G, Hartmann J, Niedermeyer G, Deckert J, Ransmayr G, Heinsen H, Beckmann H, Riederer P (1994) Excitotoxins L-beta-oxalyl-amino-alanine (L-BOAA) and 3,4,6-trihydroxyphenylalanine (6-OH-DOPA) inhibit [3H]alpha-amino-3-hydroxy-5-me thyl-4-isoxazole-propionic acid (AMPA) binding in human hippocampus. Neurosci Lett 169: 219–222Google Scholar
  10. Metodiewa D, Reszka K, Dunford HB (1989) Oxidation of the substituted catechols dihydroxyphenylalanine methyl ester and trihydroxyphenylalanine by lactoperoxidase and its compounds. Arch Biochem Biophys 274: 601–608Google Scholar
  11. Morrison ME, Yagi MJ, Cohen G (1985) In vitro studies of 2,4-dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. Proc Natl Acad Sci 82: 2960–2964Google Scholar
  12. Olney JW, Zorumski CF, Stewart GR, Price MT, Wang GH, Labruyere J (1990) Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases. Exp Neurol 108: 269–272Google Scholar
  13. Ong HH, Creveling CR, Daly JW (1969) The synthesis of 2,4,5-trihydroxyphenylalanine (6-hydroxydopa). A centrally active norepinephrine-depleting agent. J Med Chem 12: 458–462Google Scholar
  14. Pedersen JZ, el-Sherbini S, Finazzi-Agro A, Rotilio G (1992) A substrate-cofactor free radical intermediate in the reaction mechanism of copper amine oxidase. Biochemistry 31: 8–12Google Scholar
  15. Pichorner H, Metodiewa D, Winterbourn CC (1995) Generation of superoxide and tyrosine peroxide as a result of tyrosyl radical scavenging by glutathione. Arch Biochem Biophys 323: 429–437Google Scholar
  16. Rosenberg PA, Loring R, Xie Y, Zaleskas V, Aizenman E (1991) 2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin. Proc Natl Acad Sci 88: 4865–4869Google Scholar
  17. Sachs C, Jonsson G (1972) Selective 6-hydroxy-DOPA induced degeneration of central and peripheral noradrenaline neurons. Brain Res 40: 563–568Google Scholar
  18. Thoenen H, Tranzer JP (1968) Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn-Schmiedebergs Arch Pharmacol Exp Pathol 261: 271–288Google Scholar
  19. Weiss JH, Koh JY, Choi DW (1989) Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons. Brain Res 497: 64–71Google Scholar
  20. Wick MM, Byers L, Ratliff J (1979) Selective toxicity of 6-hydroxydopa for melanoma cells. J Invest Dermatol 72: 67–69Google Scholar
  21. Zieher LM, Jaim-Etcheverry G (1975) Different alterations in the development of the noradrenergic innervation of the cerebellum and the brain stem produced by neonatal 6-hydroxydopa. Life Sci 17: 987–991Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • R. M. Kostrzewa
    • 1
  • R. Brus
    • 2
  1. 1.Department of PharmacologyQuillen College of Medicine, East Tennessee State UniversityTennesseeU.S.A.
  2. 2.Department of PharmacologySilesian Academy of MedicineZabrzePoland

Personalised recommendations